A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

NCT01989676

Last updated date
Study Location
Cancer Center of Central Connecticut
Plainville, Connecticut, 06062, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Metastatic Breast Cancer
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically confirmed diagnosis of breast cancer.

- Presence of metastatic disease.

- Documentation of HER2 gene amplification or overexpression.

- Available tumor tissue for central review of HER2 status.

- At least 1 measurable lesion as defined by RECIST 1.1.

- Eastern Cooperative Oncology Group status of 0 to 2.

- Left ventricular ejection fraction within institutional range of normal, measured by either two dimensional echocardiogram or multigated acquisition scan.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Relapse within 1 year of last dose of previous adjuvant (including neoadjuvant)
treatment (except endocrine therapy) and within 1 year before randomization.


- Prior systemic therapy for metastatic disease (except endocrine therapy).


- Prior cumulative dose of doxorubicin of >400 mg/m2, epirubicin dose >800 mg/m^2, or
the equivalent dose for other anthracyclines or derivatives (eg, 72 mg/m^2 of
mitoxantrone). If the patient has received more than one anthracycline, then the
cumulative dose must not exceed the equivalent of 400 mg/m^2 of doxorubicin.


- Inflammatory breast cancer.


- Active uncontrolled or symptomatic central nervous system metastases.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Metastatic Breast CancerMulticenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer
NCT01237327
  1. Beijing,
  2. Beijing,
  3. Nanjing,
  4. Nanjing,
  5. Shanghai,
  6. Tianjin,
  7. Xi'an,
Female
0+
years
MULTIPLE SITES
Metastatic Breast CancerA Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
NCT01989676
  1. Plainville, Connecticut
  2. Southington, Connecticut
  3. Boca Raton, Florida
  4. Plantation, Florida
  5. Berazategui, Buenos Aires
  6. Rosario, Santa FE
  7. San Miguel de Tucuman, Tucuman
  8. C.a.b.a,
  9. Fortaleza, CE
  10. Goiania, GO
  11. Curitiba, Parana
  12. Londrina, Parana
  13. Lajeado, RIO Grande DO SUL
  14. Ijui, RS
  15. Porto Alegre, RS
  16. Itajai, Santa Catarina
  17. Barretos, SAO Paulo
  18. Florianopolis, SC
  19. Itajai, SC
  20. Santo Andre, SP
  21. Santo Andre, SP
  22. Temuco, Region DE LA Araucania
  23. Temuco, Region DE LA Araucania
  24. Temuco, Region DE LA Araucania
  25. Temuco, Region DE LA Araucaniz
  26. Santiago, RM
  27. Vina del Mar, V Region
  28. Vina del Mar, V Region
  29. Temuco,
  30. V Region,
  31. V Region,
  32. Praha 2,
  33. Chania, Crete
  34. Pylaia, Thessaloniki
  35. Athens,
  36. Kecskemet,
  37. Miskolc,
  38. Szolnok,
  39. Szombathely,
  40. Visakhapatnam, Andhra Pradesh
  41. Bengaluru, Karnataka
  42. Manipal, Karnataka
  43. Mumbai, Maharashtra
  44. Nashik, Maharashtra
  45. Navi Mumbai, Maharashtra
  46. Pune, Maharashtra
  47. Pune, Maharashtra
  48. Pune, Maharashtra
  49. Cuttack, Odisha
  50. Bikaner, Rajasthan
  51. Madurai, Tamil NADU
  52. Hyderabad, Telangana
  53. Nagoya, Aichi
  54. Fukuoka-Shi, Fukuoka
  55. Kurume-city, Fukuoka
  56. Sapporo, Hokkaido
  57. Kumamoto-city, Kumamoto
  58. Kitaadachi-gun, Saitama
  59. Bunkyo-ku, Tokyo
  60. Meguro-Ku, Tokyo
  61. Shinagawa-ku, Tokyo
  62. Chiba,
  63. Kagoshima,
  64. Niigata,
  65. Osaka,
  66. Osaka,
  67. Shizuoka,
  68. Cheongju-si, Chungcheongbuk-do
  69. Ulsan, Korea
  70. Busan,
  71. Daegu,
  72. Goyang-si,
  73. Seoul,
  74. Seoul,
  75. Seoul,
  76. Riga,
  77. Mexico City, Distrito Federal
  78. Mexico, Distrito Federal
  79. Mexico, Distrito Federal
  80. Oaxaca,
  81. Queretaro,
  82. Lima,
  83. Lima,
  84. Lima,
  85. Lima,
  86. Lima,
  87. Lima,
  88. Lima,
  89. Lima,
  90. Lima,
  91. Lima,
  92. Cebu City, Cebu
  93. San Juan City, Mentro Manila
  94. Manila, Metro Manila
  95. Quezon City, Metro Manila
  96. Manila, NCR
  97. Pasig City, NCR
  98. Quezon City, NCR
  99. Cebu City, Region VII
  100. Manila,
  101. Gdansk,
  102. Gdynia,
  103. Lodz,
  104. Olsztyn,
  105. Rzeszow,
  106. Warszawa,
  107. Braga,
  108. Lisboa,
  109. Cluj-Napoca, Cluj
  110. Cluj-Napoca, Cluj
  111. Craiova, Dolj
  112. Craiova, Jud Dolj
  113. Bucuresti,
  114. Sibiu,
  115. Suceava,
  116. Timisoara,
  117. Grozny, Chechenkaya Republic
  118. Kislino Settlement, Kursk
  119. Kuzmolovo, Vsevolozhskiy, Leningrad Region
  120. Saint-Petersburg, Pos.pesochny
  121. Saint-Petersburg, Poselok Pescochny
  122. Ufa, Republic OF Bashkortostan
  123. Ufa, Republic OF Baskortostan
  124. Ufa, Republic OF Baskortostan
  125. Petrozavodsk, Republic OF Karelia
  126. Saransk, Republic OF Mordovia
  127. Rostov-on-Don, Rostov Region
  128. Pushkin, Saint Petersburg
  129. Pesochniy, Saint-petersburg
  130. Poselok Pesochny, Saint-petersburg
  131. Kislovodsk, Stavropol Region
  132. Lermomtov, Stavropol Region
  133. Pyatigorsk, Stavropol Region
  134. Pyatigorsk, Stavropol Region
  135. Pyatigorsk, Stavropol Region
  136. Pyatigorsk, Stavropol Region
  137. Pyatigorsk, Stavropol Region
  138. Volzhskiy, Volgograd Region
  139. Volzhskiy, Volgograd Region
  140. Volzhskiy, Volgograd Region
  141. Arkhangelsk,
  142. Chelyabinsk,
  143. Chelyabinsk,
  144. Ivanovo,
  145. Kaluga,
  146. Magnitogorsk,
  147. Moscow,
  148. Moscow,
  149. Moscow,
  150. Moscow,
  151. Nizhniy Novgorod,
  152. Nizhniy Novgorod,
  153. Nizhniy Novgorod,
  154. Nizhniy Novgorod,
  155. Omsk,
  156. Orel,
  157. Perm,
  158. Petrozavodsk,
  159. Ryazan,
  160. Saint Petersburg,,
  161. Saint Petersburg,
  162. Saint Petersburg,
  163. Saint Petersburg,
  164. Saint Petersburg,
  165. Saint-Petersburg,
  166. Saint-Petersburg,
  167. Saint-Petersburg,
  168. Saint-Petersburg,
  169. Saint-Petersburg,
  170. Saratov,
  171. Saratov,
  172. Stavropol,
  173. Volgograd,
  174. Volzhskiy,
  175. Belgrade,
  176. Belgrade,
  177. Nis,
  178. Sremska Kamenica,
  179. Bratislava,
  180. Bratislava,
  181. Port Elizabeth, Eastern CAPE
  182. Johannesburg, Gauteng
  183. Johannesburg, Gauteng
  184. Johannesburg, Gauteng
  185. Johannesburg, Gauteng
  186. Johannesburg, Gauteng
  187. Johannesburg, Gauteng
  188. Johannesburg, Gauteng
  189. Johannesburg, Gauteng
  190. Johannesburg, Gauteng
  191. Johannesburg, Gauteng
  192. Johannesburg, Gauteng
  193. Johannesburg, Gauteng
  194. Parktown, Gauteng
  195. Pretoria, Gauteng
  196. Pretoria, Gauteng
  197. Cape Town, Western CAPE
  198. Cape Town, Western CAPE
  199. Cape Town, Western CAPE
  200. Kraaifontein, Western CAPE
  201. Parow, Western CAPE
  202. Rondebosch, Western CAPE
  203. Bangkapi, Bangkok
  204. Jatujak, Bangkok
  205. Jatujak, Bangkok
  206. Ratchathewi, Bangkok
  207. Suanluang, Bangkok
  208. Muang, Kanchanaburi
  209. Muang, Nonthaburi
  210. Amphur Muang, Udonthani
  211. Bangkok,
  212. Khon Khaen,
  213. Udonthani,
  214. Adana,
  215. Ankara,
  216. Bursa,
  217. Diyarbakir,
  218. Gaziantep,
  219. Istanbul,
  220. Chernivtsi,
  221. Dnipropetrovsk,
  222. Kharkiv,
  223. Kharkiv,
  224. Khmelnytskyi,
  225. Kryvyi Rih,
  226. Kyiv,
  227. Lviv,
  228. Odesa,
  229. Uzhgorod,
  230. Vinnytsia,
Female
18 Years+
years
MULTIPLE SITES
Metastatic Breast CancerPalbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
NCT01942135
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Daphne, Alabama
  5. Mobile, Alabama
  6. Mobile, Alabama
  7. Mobile, Alabama
  8. Avondale, Arizona
  9. Chandler, Arizona
  10. Flagstaff, Arizona
  11. Gilbert, Arizona
  12. Glendale, Arizona
  13. Glendale, Arizona
  14. Goodyear, Arizona
  15. Mesa, Arizona
  16. Mesa, Arizona
  17. Prescott Valley, Arizona
  18. Sedona, Arizona
  19. Surprise, Arizona
  20. Tucson, Arizona
  21. Tucson, Arizona
  22. Bakersfield, California
  23. Culver City, California
  24. Culver City, California
  25. Duarte, California
  26. Fullerton, California
  27. Glendale, California
  28. La Jolla, California
  29. La Jolla, California
  30. La Jolla, California
  31. Los Angeles, California
  32. Los Angeles, California
  33. Los Angeles, California
  34. Los Angeles, California
  35. Los Angeles, California
  36. Los Angeles, California
  37. Los Angeles, California
  38. Los Angeles, California
  39. Los Angeles, California
  40. Los Angeles, California
  41. Los Angeles, California
  42. Los Angeles, California
  43. Los Angeles, California
  44. Los Angeles, California
  45. Los Angeles, California
  46. Los Angeles, California
  47. Los Angeles, California
  48. Orange, California
  49. Orange, California
  50. Orange, California
  51. Pasadena, California
  52. Redondo Beach, California
  53. San Diego, California
  54. San Francisco, California
  55. San Luis Obispo, California
  56. Santa Ana, California
  57. Santa Maria, California
  58. Santa Monica, California
  59. South Pasadena, California
  60. West Hills, California
  61. Aurora, Colorado
  62. Aurora, Colorado
  63. Aurora, Colorado
  64. Aventura, Florida
  65. Deerfield Beach, Florida
  66. Fort Lauderdale, Florida
  67. Hollywood, Florida
  68. Hollywood, Florida
  69. Hollywood, Florida
  70. Miami Beach, Florida
  71. Miami Beach, Florida
  72. Miami, Florida
  73. Orlando, Florida
  74. Pembroke Pines, Florida
  75. Pembroke Pines, Florida
  76. Pembroke Pines, Florida
  77. Plantation, Florida
  78. Atlanta, Georgia
  79. Fayetteville, Georgia
  80. Marietta, Georgia
  81. Chicago, Illinois
  82. Zion, Illinois
  83. Brunswick, Maine
  84. Kennebunk, Maine
  85. Scarborough, Maine
  86. Baltimore, Maryland
  87. Lutherville, Maryland
  88. Ann Arbor, Michigan
  89. Grand Rapids, Michigan
  90. Edina, Minnesota
  91. Minneapolis, Minnesota
  92. Minneapolis, Minnesota
  93. Minneapolis, Minnesota
  94. Ballwin, Missouri
  95. Chesterfield, Missouri
  96. Saint Louis, Missouri
  97. Saint Louis, Missouri
  98. Saint Louis, Missouri
  99. Washington, Missouri
  100. Washington, Missouri
  101. Henderson, Nevada
  102. Las Vegas, Nevada
  103. Las Vegas, Nevada
  104. Las Vegas, Nevada
  105. Las Vegas, Nevada
  106. New Brunswick, New Jersey
  107. Brewster, New York
  108. Lake Success, New York
  109. Mount Kisco, New York
  110. Mount Kisco, New York
  111. Asheville, North Carolina
  112. Asheville, North Carolina
  113. Monroeville, Pennsylvania
  114. Philadelphia, Pennsylvania
  115. Philadelphia, Pennsylvania
  116. Philadelphia, Pennsylvania
  117. Philadelphia, Pennsylvania
  118. Pittsburgh, Pennsylvania
  119. Pittsburgh, Pennsylvania
  120. Pittsburgh, Pennsylvania
  121. Germantown, Tennessee
  122. Dallas, Texas
  123. Fort Worth, Texas
  124. Longview, Texas
  125. McAllen, Texas
  126. San Antonio, Texas
  127. San Antonio, Texas
  128. San Antonio, Texas
  129. Tyler, Texas
  130. Weslaco, Texas
  131. Salt Lake City, Utah
  132. Salt Lake City, Utah
  133. Arlington, Virginia
  134. Charlottesville, Virginia
  135. Charlottesville, Virginia
  136. Charlottesville, Virginia
  137. Fairfax, Virginia
  138. Fairfax, Virginia
  139. Fairfax, Virginia
  140. Leesburg, Virginia
  141. Norfolk, Virginia
  142. Norfolk, Virginia
  143. Virginia Beach, Virginia
  144. Winchester, Virginia
  145. Seattle, Washington
  146. Seattle, Washington
  147. Seattle, Washington
  148. Mequon, Wisconsin
  149. Milwaukee, Wisconsin
  150. Bankstown, New South Wales
  151. Waratah, New South Wales
  152. Auchenflower, Queensland
  153. Nambour, Queensland
  154. Southport, Queensland
  155. Brighton, Victoria
  156. Clayton, Victoria
  157. East Melbourne, Victoria
  158. Footscray, Victoria
  159. Frankston, Victoria
  160. Geelong, Victoria
  161. Malvern, Victoria
  162. Melbourne, Victoria
  163. St Albans, Victoria
  164. Murdoch, Western Australia
  165. Edegem, Antwerpen
  166. Ottignies, Brabant Wallon
  167. Bruxelles, Bruxelles Capitale
  168. Charleroi, Hainaut
  169. Haine St. Paul, Hainaut
  170. Tournai, Hainaut
  171. Libramont-Chevigny, Luxembourg
  172. Bruxelles, Region DE Bruxelles-capital
  173. Bonheiden,
  174. Bruxelles,
  175. Leuven,
  176. Namur,
  177. Wilrijk,
  178. Kelowna, British Columbia
  179. Surrey, British Columbia
  180. Barrie, Ontario
  181. Kingston, Ontario
  182. Oshawa, Ontario
  183. Ottawa, Ontario
  184. St. Catharines, Ontario
  185. Toronto, Ontario
  186. Toronto, Ontario
  187. Toronto, Ontario
  188. Montreal, Quebec
  189. Leipzig,
  190. Leipzig,
  191. München,
  192. München,
  193. Cork,
  194. Bagno A Ripoli (FI),
  195. Bagno A Ripoli (FI),
  196. Bologna,
  197. Bologna,
  198. Catania,
  199. Legnago (VR),
  200. Legnago (VR),
  201. Meldola (FC),
  202. Milano,
  203. Milano,
  204. Milano,
  205. Milano,
  206. Milano,
  207. Modena,
  208. Napoli,
  209. Roma,
  210. Roma,
  211. Terni,
  212. Nagoya, Aichi
  213. Kashiwa, Chiba
  214. Matsuyama-city, Ehime
  215. Kita-adachi-gun, Saitama,japan
  216. Chiba,
  217. Fukuoka,
  218. Kagoshima,
  219. Osaka,
  220. Goyang-si, Gyeonggi-do
  221. Seongnam-si, Gyeonggi-do
  222. Seoul,
  223. Seoul,
  224. Seoul,
  225. Maastricht, Limburg
  226. Sittard-Geleen, Limburg
  227. Tilburg, Noord-brabant
  228. Den Haag, Zuid-holland
  229. Leiden, Zuid-holland
  230. Rotterdam, Zuid-holland
  231. Lisboa,
  232. Porto,
  233. Bucharest,
  234. Ploiesti,
  235. Suceava,
  236. Tg Mures,
  237. Belgorod,, Belgorodskaya Oblast',
  238. Stariy Oskol, Belgorodskaya Oblast'
  239. Village Kuzmolovsky, Leningradskaya Oblast'
  240. Ufa, Republic OF Bashkortostan
  241. Lermontov, Stavropol Territory
  242. Pyatigorsk,, Stavropol Territory
  243. Chelyabinsk,
  244. Moscow,
  245. Saint Petersburg,
  246. Saint Petersburg,
  247. Stavropol,
  248. Village Pesochny,
  249. Tainan,
  250. Taipei,
  251. Izmir, Bornova
  252. Chernivtsi,
  253. Dnipro,
  254. Kharkiv,
  255. Lviv,
  256. Odesa,
  257. Vinnytsia,
  258. Portsmouth, Hampshire
  259. Cardiff, South Glamorgan
  260. Sheffield, South Yorkshire
  261. Sheffield, South Yorkshire
  262. London,
  263. Sutton,
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
Official Title  ICMJE A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER
Brief Summary The current study will compare the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280014 in combination with paclitaxel versus trastuzumab sourced from the European Union (trastuzumab-EU) with paclitaxel in female patients with HER2-positive, metastatic breast cancer in the first-line treatment setting. The hypothesis to be tested in this study is that the efficacy (ORR) of PF-05280014 is similar to trastuzumab-EU.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Metastatic Breast Cancer
Intervention  ICMJE
  • Biological: PF-05280014
    Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the PF-05280014 regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
    Other Name: Trastuzumab-Pfizer
  • Drug: Paclitaxel
    A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m^2 and then 60 mg/m^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
  • Biological: Herceptin®
    Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion weekly until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the Herceptin® regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
    Other Name: Trastuzumab (EU)
Study Arms  ICMJE
  • Experimental: PF-05280014
    Interventions:
    • Biological: PF-05280014
    • Drug: Paclitaxel
  • Active Comparator: Herceptin®
    Interventions:
    • Biological: Herceptin®
    • Drug: Paclitaxel
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: December 21, 2017)
707
Original Estimated Enrollment  ICMJE
 (submitted: November 14, 2013)
690
Estimated Study Completion Date  ICMJE June 27, 2020
Actual Primary Completion Date August 24, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histologically confirmed diagnosis of breast cancer.
  • Presence of metastatic disease.
  • Documentation of HER2 gene amplification or overexpression.
  • Available tumor tissue for central review of HER2 status.
  • At least 1 measurable lesion as defined by RECIST 1.1.
  • Eastern Cooperative Oncology Group status of 0 to 2.
  • Left ventricular ejection fraction within institutional range of normal, measured by either two dimensional echocardiogram or multigated acquisition scan.

Exclusion Criteria:

  • Relapse within 1 year of last dose of previous adjuvant (including neoadjuvant) treatment (except endocrine therapy) and within 1 year before randomization.
  • Prior systemic therapy for metastatic disease (except endocrine therapy).
  • Prior cumulative dose of doxorubicin of >400 mg/m2, epirubicin dose >800 mg/m^2, or the equivalent dose for other anthracyclines or derivatives (eg, 72 mg/m^2 of mitoxantrone). If the patient has received more than one anthracycline, then the cumulative dose must not exceed the equivalent of 400 mg/m^2 of doxorubicin.
  • Inflammatory breast cancer.
  • Active uncontrolled or symptomatic central nervous system metastases.
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Gender Based Eligibility:Yes
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Brazil,   Chile,   Czechia,   Greece,   Hungary,   India,   Japan,   Korea, Republic of,   Latvia,   Mexico,   Peru,   Philippines,   Poland,   Portugal,   Romania,   Russian Federation,   Serbia,   Slovakia,   South Africa,   Thailand,   Turkey,   Ukraine,   United States
Removed Location Countries Czech Republic,   Paraguay,   Puerto Rico,   Singapore,   Spain
 
Administrative Information
NCT Number  ICMJE NCT01989676
Other Study ID Numbers  ICMJE B3271002
REFLECTIONS B327-02
2013-001352-34 ( EudraCT Number )
B3271002 ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP